More Than 150 Industry Players Across The World Are Presently Engaged In Evaluating The Potential Of Nearly 300 Next Generation Immune Checkpoint Modulators For The Treatment Of Multiple Disease Indications, Claims Roots Analysis

>

More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications, claims Roots Analysis

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

 

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

  • Target Disease Indication 
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Lupus Nephritis
  • Melanoma
  • Multiple Myeloma
  • Primary Sjögren's Syndrome
  • Others 

 

  • Target Immune Checkpoint
  • B7-H3
  • CD38
  • CD40
  • CD47
  • Others

 

  • Mechanism of Action
  • Inhibitory
  • Stimulatory

 

  • Therapeutic Modality
  • Monoclonal Antibody
  • Small Molecule

 

  • Type of Therapy 
  • Monotherapy 
  • Combination Therapy

 

  • Route of Administration
  • Intravenous
  • Subcutaneous
  • Others

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific and the Rest of the World 

 

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain:

  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Incyte
  • Novartis
  • Trillium Therapeutics

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Current Market Landscape: Clinical and Preclinical Molecules

  4. Market Landscape: Therapies Targeting Cd47

  5. Market Landscape: Therapies Targeting 4-1bb

  6. Clinical Trial Analysis

  7. Company Profiles: Next Generation Inhibitors and Stimulators

  8. Academic Grants Analysis

  9. Partnerships and Collaborations

  10. Target Competitiveness Analysis

  11. Big Pharma Initiatives

  12. Market Forecast and Opportunity Analysis

  13. Concluding Remarks

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

Share:

Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report,global

Comments

Other related blogs

Global Acrylic Teeth Market- Industry Analysis and Forecast (2020-2027)

By : Maximize Market

Global Acrylic Teeth Market is expected to reach US$ XX Mn by 2027, at a nearby CAGR of 10.2% during..


The nuclear medicine and radiopharmaceuticals manufacturing market is projected to grow at an annualized rate of over 10%, till 2030

By : Roots Analysis

  Roots Analysis has announced the addition of “Nuclear Medicine and Radiopharmaceutical..


The nuclear medicine and radiopharmaceutical manufacturing market is estimated to be more than USD 6 billion in 2030, predicts Roots Analysis

By : Roots Analysis

  The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applic..